Close Menu

NEW YORK – A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who harbor DNA damage repair (DDR) gene mutations may have an improved response to platinum chemotherapy compared to those without such mutations, according to a study recently published in the Journal of Clinical Oncology: Precision Oncology.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.